MTNB RSI Chart
Last 7 days
-5.6%
Last 30 days
-10.5%
Last 90 days
-26.1%
Trailing 12 Months
-58.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 4.3M | 3.2M | 2.2M | 1.1M |
2022 | 0 | 0 | 0 | 3.2M |
2021 | 0 | 0 | 0 | 0 |
2020 | 0 | 0 | 0 | 0 |
2019 | 0 | 179.6K | 89.8K | 89.8K |
2018 | 164.7K | 209.6K | 164.7K | 119.8K |
2017 | 151.8K | 119.7K | 104.8K | 149.7K |
2015 | 0 | 0 | 0 | 194.5K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jun 22, 2022 | conrad herbert j | gifted | - | - | 1,358,120 | - |
Jun 22, 2022 | conrad herbert j | gifted | - | - | -1,358,120 | - |
Dec 31, 2021 | wikler matthew | acquired | - | - | 7,859 | - |
Sep 30, 2021 | wikler matthew | acquired | - | - | 6,106 | - |
Sep 03, 2021 | mannino raphael j | acquired | - | - | 462,150 | chief scientific officer |
Aug 04, 2021 | conrad herbert j | gifted | - | - | 494,622 | - |
Aug 04, 2021 | conrad herbert j | gifted | - | - | -494,622 | - |
Jul 07, 2021 | conrad herbert j | gifted | - | - | -1,280,920 | - |
Jul 07, 2021 | conrad herbert j | gifted | - | - | 1,280,920 | - |
Jun 30, 2021 | wikler matthew | acquired | - | - | 10,244 | - |
Which funds bought or sold MTNB recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | National Wealth Management Group, LLC | unchanged | - | 2,288 | 11,314 | 0.01% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | added | 47,644 | 35,135 | 35,193 | -% |
May 15, 2024 | Bayesian Capital Management, LP | sold off | -100 | -4,065 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -26.84 | -708 | 7,913 | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | sold off | -100 | -4,127 | - | -% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | reduced | -72.54 | -13,681 | 7,182 | -% |
May 15, 2024 | Royal Bank of Canada | added | 44.43 | 1,000 | 3,000 | -% |
May 15, 2024 | Steward Partners Investment Advisory, LLC | unchanged | - | 167 | 824 | -% |
May 15, 2024 | MORGAN STANLEY | added | 72.75 | 6,928 | 12,874 | -% |
May 15, 2024 | STATE STREET CORP | reduced | -7.38 | 24,789 | 178,825 | -% |
Unveiling Matinas BioPharma Holdings Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Matinas BioPharma Holdings Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Matinas BioPharma Holdings Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q4 | 2020Q3 | 2019Q4 | 2019Q4 | 2019Q3 | 2019Q2 | 2018Q4 | 2018Q3 |
Revenue | - | - | - | - | - | 1,096 | 1,063 | 1,063 | 1,063 | 532 | - | 19.00 | 38.00 | 57.00 | 77.00 | 96.00 | 64.00 | 32.00 | - | 90.00 | - | - |
Costs and Expenses | 0.3% | 5,902 | 5,887 | 6,134 | 6,159 | 6,682 | 6,543 | 6,525 | 6,988 | 6,714 | 6,878 | 4,790 | 6,386 | 6,551 | - | 5,700 | 5,736 | - | 4,561 | 4,610 | 4,167 | 2,954 |
S&GA Expenses | -100.0% | - | 2,222 | 2,839 | 2,600 | 2,712 | 2,677 | 2,818 | 2,861 | 2,474 | 2,257 | 2,309 | 3,145 | 3,026 | - | 2,364 | 2,316 | - | 1,890 | 1,782 | 2,474 | 1,575 |
R&D Expenses | -6.0% | 3,446 | 3,665 | 3,295 | 3,559 | 3,970 | 3,867 | 3,707 | 4,127 | 4,240 | 4,621 | 2,481 | 3,241 | 3,526 | - | 3,336 | 3,420 | - | 2,671 | 2,829 | 1,692 | 1,380 |
Net Income | -9.6% | -5,824 | -5,314 | -6,055 | -6,060 | -5,513 | -3,634 | -5,462 | -5,923 | -6,699 | -6,836 | -4,791 | -4,956 | -6,340 | - | -5,449 | -5,572 | - | -4,404 | -3,344 | -3,626 | -2,935 |
Net Income Margin | -1.4% | -21.22* | -20.93* | -9.85* | -6.41* | -4.79* | -6.59* | -267.92* | -283.22* | -259.24* | -255.25* | -239.81* | -248.93* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -26.0% | -5,769 | -4,579 | -4,435 | -2,235 | -4,129 | -4,341 | -5,220 | -5,186 | -3,993 | -5,973 | -864 | -4,651 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -21.9% | 20.00 | 25.00 | 30.00 | 34.00 | 38.00 | 45.00 | 48.00 | 52.00 | 56.00 | 61.00 | 67.00 | 70.00 | 72.00 | 71.00 | 75.00 | 79.00 | 84.00 | 40.00 | 45.00 | 48.00 | 51.00 |
Current Assets | -33.8% | 10.00 | 16.00 | 20.00 | 24.00 | 28.00 | 35.00 | 37.00 | 42.00 | 45.00 | 51.00 | 56.00 | 61.00 | 63.00 | 62.00 | 65.00 | 69.00 | 74.00 | 30.00 | 34.00 | 37.00 | 40.00 |
Cash Equivalents | -77.6% | 1.00 | 5.00 | 6.00 | 10.00 | 6.00 | 7.00 | 11.00 | 10.00 | 19.00 | 21.00 | 25.00 | 30.00 | 23.00 | 12.00 | 7.00 | 15.00 | 10.00 | 22.00 | 33.00 | 37.00 | 39.00 |
Net PPE | -4.9% | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
Goodwill | 0% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | -13.8% | 5.00 | 6.00 | 7.00 | 6.00 | 6.00 | 8.00 | 9.00 | 10.00 | 8.00 | 9.00 | 9.00 | 7.00 | 6.00 | 7.00 | 7.00 | 6.00 | 7.00 | 7.00 | 7.00 | 8.00 | 8.00 |
Current Liabilities | -23.8% | 2.00 | 3.00 | 3.00 | 3.00 | 2.00 | 4.00 | 5.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 2.00 | 4.00 | 3.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
Shareholder's Equity | -24.4% | 15.00 | 19.00 | 23.00 | 28.00 | 33.00 | 37.00 | 39.00 | 43.00 | 48.00 | 52.00 | 58.00 | 63.00 | 67.00 | 64.00 | 68.00 | 73.00 | 78.00 | 33.00 | 38.00 | 40.00 | 43.00 |
Retained Earnings | -3.3% | -181 | -175 | -170 | -164 | -158 | -152 | -149 | -143 | -137 | -131 | -124 | -118 | -112 | -107 | -101 | -95.72 | -89.42 | -84.38 | -78.80 | -73.81 | -70.00 |
Additional Paid-In Capital | 0.5% | 196 | 195 | 194 | 193 | 191 | 190 | 189 | 187 | 186 | 184 | 183 | 181 | 175 | 167 | 165 | 164 | 163 | 113 | 113 | 105 | 103 |
Shares Outstanding | 0.1% | 217 | 217 | 217 | 217 | 217 | 217 | 217 | 217 | 217 | 216 | 215 | 205 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 76.00 | - | - | - | 165 | - | - | - | 160 | - | - | - | 142 | - | - | - | 112 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -26.0% | -5,769 | -4,579 | -4,419 | -2,193 | -4,087 | -4,299 | -4,970 | -5,131 | -4,756 | -3,957 | -5,749 | -864 | -4,651 | -4,307 | -5,226 | -3,168 | -4,664 | -4,898 | -4,073 | -2,096 | -3,023 |
Share Based Compensation | -21.8% | 995 | 1,272 | 1,196 | 1,208 | 1,272 | 1,340 | 1,413 | 1,215 | 1,260 | 1,074 | 1,061 | 1,056 | 1,101 | 1,220 | 953 | 945 | 1,447 | 688 | 671 | 822 | 804 |
Cashflow From Investing | -32.4% | 2,000 | 2,960 | 1,084 | 6,198 | 3,000 | -42.00 | 5,750 | -3,792 | 2,961 | 57.00 | 243 | 7,654 | 8,817 | 9,089 | -2,780 | 7,991 | -54,967 | -5,605 | -73.43 | -317 | -14.25 |
Cashflow From Financing | 5400.0% | 53.00 | -1.00 | -1.00 | -1.00 | -4.00 | -5.00 | -3.00 | -6.00 | 93.00 | 8.00 | -8.32 | 180 | 6,785 | 550 | 54.00 | 4.00 | 47,439 | 10.00 | -19.53 | -167 | 30,028 |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue: | ||
Contract revenue | $ 1,096 | |
Costs and Expenses: | ||
Research and development | 3,446 | 3,970 |
General and administrative | 2,456 | 2,712 |
Total costs and expenses | 5,902 | 6,682 |
Loss from operations | (5,902) | (5,586) |
Other income, net | 78 | 73 |
Net loss | $ (5,824) | $ (5,513) |
Net loss per share - basic | $ (0.03) | $ (0.03) |
Net loss per share - diluted | $ (0.03) | $ (0.03) |
Weighted average common shares outstanding: | ||
Weighted average common shares outstanding - basic | 217,358,085 | 217,264,526 |
Weighted average common shares outstanding - diluted | 217,358,085 | 217,264,526 |
Other comprehensive gain, net of tax | ||
Unrealized gain on securities available-for-sale | $ 87 | $ 229 |
Other comprehensive gain, net of tax | 87 | 229 |
Comprehensive loss | $ (5,737) | $ (5,284) |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 1,071 | $ 4,787 |
Marketable debt securities | 7,039 | 8,969 |
Restricted cash – security deposit | 50 | 50 |
Prepaid expenses and other current assets | 2,129 | 1,737 |
Total current assets | 10,289 | 15,543 |
Non-current assets: | ||
Leasehold improvements and equipment – net | 1,829 | 1,923 |
Operating lease right-of-use assets – net | 2,919 | 3,064 |
Finance lease right-of-use assets – net | 20 | 21 |
In-process research and development | 3,017 | 3,017 |
Goodwill | 1,336 | 1,336 |
Restricted cash – security deposit | 200 | 200 |
Total non-current assets | 9,321 | 9,561 |
Total assets | 19,610 | 25,104 |
Current liabilities: | ||
Accounts payable | 473 | 514 |
Accrued expenses | 839 | 1,447 |
Operating lease liabilities – current | 681 | 656 |
Financing lease liabilities – current | 5 | 5 |
Total current liabilities | 1,998 | 2,622 |
Non-current liabilities: | ||
Deferred tax liability | 341 | 341 |
Operating lease liabilities – net of current portion | 2,697 | 2,877 |
Financing lease liabilities – net of current portion | 16 | 18 |
Total non-current liabilities | 3,054 | 3,236 |
Total liabilities | 5,052 | 5,858 |
Stockholders’ equity: | ||
Common stock par value $0.0001 per share, 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 217,482,830 and 217,264,526 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 22 | 22 |
Additional paid-in capital | 196,067 | 195,018 |
Accumulated deficit | (181,397) | (175,573) |
Accumulated other comprehensive loss | (134) | (221) |
Total stockholders’ equity | 14,558 | 19,246 |
Total liabilities and stockholders’ equity | $ 19,610 | $ 25,104 |